COVID-19

R&D

Seeing double: the rise of digital twins in life sciences

Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D).

News

CureVac and GSK try again with COVID-19 vaccine

CureVac and GlaxoSmithKline's first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical tria

R&D

Vaccine equity: how the pandemic demonstrated global health ...

With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines.

News

FDA restricts GSK's Xevudy due to lower efficacy against BA....

GlaxoSmithKline and Vir's Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus.

News

Moderna follows Pfizer in asking FDA for second COVID booste...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty

Digital

Will people be left behind by the digital health revolution?

The uptake of digital health tools during the pandemic has been enormous due to improved access they provide to healthcare.

Seeing double: the rise of digital twins in life sciences

CureVac and GSK try again with COVID-19 vaccine

Vaccine equity: how the pandemic demonstrated global health ...

FDA restricts GSK's Xevudy due to lower efficacy against BA....

Moderna follows Pfizer in asking FDA for second COVID booste...

Will people be left behind by the digital health revolution?

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

COVID-19

Editor's Picks